Bambusa Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BBTX | BCAX | ABCL | OABI | STTK | ACRS | |
|---|---|---|---|---|---|---|
| Market cap | 799.67M | 588.28M | 3.98B | 755.56M | 516.87M | 570.34M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -2.6 | -16.1 | -19.9 | -10.0 | -5.1 |
| Price/book | -1.8 | 1.3 | 4.2 | 3.0 | 2.5 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.20% | −38.98% | +171.08% | +275.36% | +162.76% | +62.11% |
| Today | +0.44% | −0.78% | +0.82% | +0.58% | −5.85% | −1.60% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BBTX news ›Latham & Watkins Advises on Bambusa Therapeutics’ Upsized US$168.9 Million IPO
Legal Desire is leading online legal news and insights platform, delivering comprehensive coverage of legal industry news, judgments, legal analysis, law firm updates, career guidance for lawyers, and policy insights. Trusted by legal…
Immunology and inflammation biotech Bambusa Therapeutics prices upsized IPO at $16 midpoint
BBTX IPO News - Immunology and inflammation biotech Bambusa Therapeutics prices upsized IPO at $16 midpoint Renaissance Capital Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, raised $169…
More from 1 other outlet
Bambusa Therapeutics prices upsized initial public offering on Nasdaq
Clinical-stage biopharmaceutical firm Bambusa Therapeutics priced its upsized initial public offering on the Nasdaq Stock Market under the ticker symbol BBTX to fund antibody development. Bambusa Therapeutics prices upsized initial public…
Bambusa Therapeutics Rings the Opening Bell
About This EventBambusa Therapeutics (Nasdaq: BBTX), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, visits the Nasdaq MarketSite in Times…
Immunology and inflammation biotech Bambusa Therapeutics sets terms for $150 million IPO
BBTX IPO News - Immunology and inflammation biotech Bambusa Therapeutics sets terms for $150 million IPO Renaissance Capital Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, announced…
Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on
Oct 26 (Reuters) - Drug developers Aspen Neuroscience and Bambusa Therapeutics launched their US initial public offering roadshows on Monday, adding to a wave of issuers from the biotech industry that have tapped the fall IPO window. The…
Bambusa, A Next-Generation Bispecific Antibody Developer, Set For Nasdaq Debut On October 30
RTTNews Bambusa, A Next-Generation Bispecific Antibody Developer, Set For Nasdaq Debut On October 30 Bambusa Therapeutics Inc. is set to begin trading on the Nasdaq Global Select Market on October 30, 2026,
Bambusa Therapeutics slips 6.3% in first day after $168.9 million IPO
Bambusa sold shares at $16 in its U.S. IPO, pulling in $168.9 million. The stock then finished its first session at $14.99, a 6.3% slide from the offer price. At that closing level, the company was valued near $763.6 million, based on the…
Non-controlling/minority interest of BAMBUSA THERAPEUTICS INC – NASDAQ:BBTX
TradingView Non-controlling/minority interest of BAMBUSA THERAPEUTICS INC
Bambusa, Clinical-Stage Bispecific Antibody Developer, Files for Nasdaq IPO
TradingView Bambusa, Clinical-Stage Bispecific Antibody Developer, Files for Nasdaq IPO Bambusa Therapeutics, Inc. priced its initial public offering at $16.00 per share, offering 10,555,555 shares of common stock. The offe
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- prnewswire.com3
- renaissancecapital.com3
- 247wallst.com2
- briefs.co2
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.